We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

New analysis presented by the company, together with an improved discount to the price of vamorolone, mean that NICE can now ...

Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The following considerations around implementing the evidence generation process have been identified through working with system partners: ...

NICE's medical technologies advisory committee considered evidence on digital technologies to support self-management of chronic obstructive pulmonary disease (COPD) from several sources, including an ...

All the technologies that have been recommended for use in the NHS while more evidence is generated have some clinical evidence suggesting that they may improve symptoms of COPD, enhance respiratory ...